Respiratory failure & ventilation
Polymorphism in interferon alpha/beta receptor contributes to glucocorticoid response and outcome of acute respiratory distress syndrome (ARDS) and coronavirus diseases (COVID-19)
Authors' conclusion
The distribution of this SNP within clinical study arms may explain the contradictory results of multiple ARDS studies and outcomes in COVID-19 concerning type I IFN signaling and glucocorticoids.
Study context
- Population
- Patients with ARDS in the phase III INTEREST trial
- Participants
- 144 vs 152
- Comparison
- IFNAR2 SNP rs9984273 minor vs major allele, in IFN β-1a vs placebo
- IFN β-1an = 144
- Placebon = 152reference
Methodological detailsgenetic association analysis, lung organ culture experiments
- Genetic association analysis
- Lung organ culture experiments
Primary result
As reported in the abstract
- Novel disease association of SNP rs9984273 in the IFNAR2 gene, in an area corresponding to a glucocorticoid receptor (GR) binding motif
- Minor allele associated with higher IFNAR expression, more rapid decrease of IFN γ and IL-6 levels and better outcome in IFN β treated patients with ARDS
- Major allele associated with poor outcome, especially under concomitant IFN β and glucocorticoid treatment
Further findings
COVID-19 severity (COVID-19 Host Genetics Initiative database)
- Minor allele of rs9984273 associated with less severe COVID-19
Original publication
Polymorphism in interferon alpha/beta receptor contributes to glucocorticoid response and outcome of ARDS and COVID-19. Crit Care. Published 16 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →